Fig. 3.

a Sankey plot showing the further stratification of the standard BluePrint (BP) Basal, Luminal, and HER2 subtypes with full-genome microarray data available, into the BP single and dual subtypes. b Sankey plot illustrating the re-classification of clinical-based subtypes (based on hormone receptors (HR) and human epidermal growth factor receptor 2 (HER2) status) to BP-based single-type molecular subtypes (Basal-single-type, Luminal-single-type, HER2-single-type). c Further stratification of the same clinical-based subtypes as in (b) to the BP-based dual subtypes (Luminal-HER2-type, Luminal-Basal-type, HER2-Basal-type, and Luminal-HER2-Basal-type). d, e Boxplots reporting for each single and dual subtype category (x-axis), the level and spread of estrogen receptor and Ki67 positivity based on Immunohistochemistry assessment (y-axis). Significant differential positivity between ER and Ki67 was assumed at a p-value < 0.05 determined with a t-test between subtype categories. To note, for 4511 of the 9573 tumor samples with clinical annotation, HR and HER2 status were not available (Table S1)